Navigation Links
Sanofi Pasteur and Statens Serum Institut Team Up Against Tuberculosis
Date:2/14/2008

Scientific Advances in Vaccine Research may Lead to Improved Vaccine

Against Leading Cause of Death in Developing Countries

LYON, France, February 14 /PRNewswire-FirstCall/ -- Sanofi pasteur, the vaccines division of the sanofi-aventis Group, announced today that it has signed a collaborative research and license agreement with the Statens Serum Institut of Denmark (SSI) for the development and marketing of a new vaccine against tuberculosis (TB), a disease that causes the death of two million people, worldwide, each year.

Under the terms of the agreement, SSI has granted sanofi pasteur a license to its technology with regard to the use of certain fusion proteins in the development of a tuberculosis vaccine. The license from SSI includes access to the Intercell IC31(R) adjuvant. If the development is successful, sanofi pasteur would manufacture the vaccine commercially.

SSI TB vaccine candidates are recombinant protein sub-units, including one currently in a Phase I clinical trial. Results from a previous study showed the SSI TB vaccine technology to provide a positive immune response. Sanofi pasteur intends to build on the successes of the SSI vaccine program.

"This agreement is a milestone for sanofi pasteur," said Wayne Pisano, President and Chief Executive Officer of sanofi pasteur, which is also working to develop a vaccine against another one of the biggest global infectious disease killers--malaria.

"The current medical arsenal is inadequate for fighting tuberculosis," Pisano continued. "Improved vaccines are desperately needed if we are to succeed in controlling this disease. Sanofi pasteur and SSI are joining forces to develop a vaccine that may have a major impact on global health by preventing a disease that currently infects one person in the world every second."(1)

According to SSI's CEO, Nils Strandberg Pedersen, M.D., this agreement is a very important step in the fight against tuberculosis
'/>"/>

SOURCE Sanofi Pasteur
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. Sanofi-aventis Announces Settlement of Average Wholesale Price Civil Suits With the U.S. Department of Justice Relating to Anzemet(R)
2. Sanofi Pasteurs Investigational H5N1 Influenza Vaccine Achieves High Immune Response at low Dosage
3. Maxygen Licenses Dengue Vaccine Technology to sanofi pasteur
4. Shareholder Class Action Filed Against Sanofi-Aventis by the Law Firm of Schiffrin Barroway Topaz & Kessler, LLP
5. Pasteuria Bioscience Taps New CEO David N. Duncan
6. Panacea Pharmaceuticals Announces the Availability of BC Detect(SM), a Serum- Based Diagnostic Test for Breast Cancer
7. Codexis Licenses New Drug Metabolite Profiling and Lead Diversification Technology From the California Institute of Technology
8. Kensey Nash to Present at the Sidoti Sixth Annual West Coast Emerging Growth Institutional Investor Forum Conference
9. Abaxis to Present at the Sidoti & Company Sixth Annual San Francisco Institutional Investor Forum Conference
10. Southern Research Institute Licenses Anti-Cancer Drug Compound to Virium Pharmaceuticals
11. Midwest Research Institute Launches Center for Biological Safety and Security (CBS2)
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/30/2014)... 30, 2014 Sales Horizons, a leader ... blended sales training programs for companies engaged in complex ... used by thousands of salespeople over 25 years in ... program can be customized to address the unique sales ... blended sales training program consists of two parts: ...
(Date:7/30/2014)... July 30, 2014 BCC Research ( ... Markets for Enzymes in Industrial Applications , the global ... nearly $7.1 billion by 2018, registering a five-year compound ... estimated to be recorded in the detergent enzyme segment ... , Enzyme technology has influenced almost every sector of ...
(Date:7/30/2014)... 30, 2014  Dyadic International, Inc. ("Dyadic") (OTCQX: ... and proprietary technologies are used to discover, develop, ... the bioenergy, bio-based chemical, biopharmaceutical and industrial enzyme ... Dubinski as Vice President and Chief Financial Officer. ... and information technology operations for Dyadic and will ...
(Date:7/30/2014)... Mass. , July 30, 2014 /PRNewswire/ ... ), a biotechnology company focused on discovering, ... unmet medical needs using RNA-targeted technologies, today ... (RXI-109-1402) with RXI-109, for the reduction of ... revision surgery, has been initiated. ...
Breaking Biology Technology:Sales Horizons Launches New Blended Sales Training Programs to Companies Engaged in Complex B2B Sales 2Sales Horizons Launches New Blended Sales Training Programs to Companies Engaged in Complex B2B Sales 3Global Market for Industrial Enzymes to Reach Nearly $7.1 Billion by 2018; Detergent Enzyme Market to Record Maximum Growth 2Global Market for Industrial Enzymes to Reach Nearly $7.1 Billion by 2018; Detergent Enzyme Market to Record Maximum Growth 3Thomas Dubinski joins Dyadic as Chief Financial Officer 2Thomas Dubinski joins Dyadic as Chief Financial Officer 3Thomas Dubinski joins Dyadic as Chief Financial Officer 4RXi Pharmaceuticals Expands Clinical Program with Initiation of Third Phase 2a Study with RXI-109 for Treatment of Hypertrophic Scars 2RXi Pharmaceuticals Expands Clinical Program with Initiation of Third Phase 2a Study with RXI-109 for Treatment of Hypertrophic Scars 3RXi Pharmaceuticals Expands Clinical Program with Initiation of Third Phase 2a Study with RXI-109 for Treatment of Hypertrophic Scars 4RXi Pharmaceuticals Expands Clinical Program with Initiation of Third Phase 2a Study with RXI-109 for Treatment of Hypertrophic Scars 5
... May 1 Advanced Life Sciences,Holdings, Inc. (Nasdaq: ... the,discovery, development and commercialization of novel drugs in ... today,announced that it will host a conference call ... on Wednesday, May 7, 2008 at 10:00,a.m. (EDT). ...
... (NASDAQ: ANPI , TSX: ANP), a global ... it has received 510(k),clearance from the U.S. Food ... and 4-0 of its Quill Self-Retaining System (SRS),Polydioxanone ... a longer-lasting,absorbable suture, which is typically used for ...
... May 1 CryoLife, Inc., (NYSE: CRY ... announced today,that Harvey Morgan has been elected to ... is a Managing Director at Bentley,Associates L.P., an ... than 35 years of investment banking experience with,significant ...
Cached Biology Technology:Advanced Life Sciences to Host 2008 First Quarter Financial Results Conference Call and Webcast 2Advanced Life Sciences to Host 2008 First Quarter Financial Results Conference Call and Webcast 3Angiotech Expands Quill(TM) SRS product offering receiving FDA 510(k) approval for smaller size diameters of Quill(TM) SRS PDO 2Angiotech Expands Quill(TM) SRS product offering receiving FDA 510(k) approval for smaller size diameters of Quill(TM) SRS PDO 3Angiotech Expands Quill(TM) SRS product offering receiving FDA 510(k) approval for smaller size diameters of Quill(TM) SRS PDO 4Harvey Morgan Joins CryoLife Board of Directors 2
(Date:7/30/2014)... increase in Impact Factors for its molecular bioscience ... (Thomson Reuters, 2014) show that Clinical Science ... Biochemistry , Biochemical Society Transactions and ... their Impact Factors. The journals are owned by ... Limited. , 2014 Impact Factors (2013 Impact Factor ...
(Date:7/30/2014)... today published new research from Bjorn Brembs, professor of ... Germany, with a proof-of-concept figure allowing readers and reviewers ... This represents an important leap forward for scientific ... the quality of a scholarly output. , Figure 3 ... data and their code to F1000Research , and ...
(Date:7/30/2014)... cancer treatment has been shown to relieve patients, ... neural transmission between the peripheral and central nervous ... of Radiation Medicine, Chinese Academy of Medical Sciences, ... rat dorsal root ganglia (DRG) to provide relief ... (0, 14.8, 29.6 MBq) were implanted separately into ...
Breaking Biology News(10 mins):Across-the-board Impact Factor increases for Portland Press Limited 2F1000Research brings static research figures to life 2
... Institute for Aging Research (IFAR) at Hebrew SeniorLife, an affiliate ... specifically milk and yogurt is associated with higher bone mineral ... on the other hand, may be associated with lower BMD ... , these findings suggest that not all dairy products are ...
... reefs are predicted to decline under the pressure of ... survive at seawater temperatures even higher than predicted for ... while most species cannot, is being investigated by researchers ... York University Abu Dhabi (NYUAD). We tend ...
... February, Dennis J. Selkoe and five other "brain teasers" will ... for this honorary doctorate VIB-KU Leuven professors Bart De ... for his scientific insights, but also for his relentless search ... that cause severe damage in the brain. "The ...
Cached Biology News:New study sheds light on link between dairy intake and bone health 2How do corals survive in the hottest reefs on the planet? 2Prevention is better than cure. Also for Alzheimer's disease! 2Prevention is better than cure. Also for Alzheimer's disease! 3Prevention is better than cure. Also for Alzheimer's disease! 4
... AgarACE Enzyme(a) is a unique agarose-digesting ... quantitative recovery of intact DNA or RNA ... thermostable that low melting point (LMP) agarose ... be equilibrated to the reaction temperature before ...
... deoxynucleotidyl transferase (TdT) is an intracellular marker ... thymocytes and minor subpopulation of bone marrow ... increased numbers of TdT cells are found ... and lymphomas. Presence of TdT thus provides ...
Request Info...
... RapidStak is a fast and ... Its high capacity and reliable ... confident walk away time than typical ... of set-up make for a seamless ...
Biology Products: